Shanghai General Healthy Information and Technology Co. Ltd.
Shanghai General Healthy Information and Technology Co., Ltd. provides pharmaceutical logistics automation, information technology, and intelligent and mobile medical solutions in China. The company's products include the Smart Pharmacy Project, an intelligent drug management system that combines software and hardware; intelligent static distribution center project, an intelligent intravenous dru… Read more
Shanghai General Healthy Information and Technology Co. Ltd. (605186) - Net Assets
Latest net assets as of September 2025: CN¥1.17 Billion CNY
Based on the latest financial reports, Shanghai General Healthy Information and Technology Co. Ltd. (605186) has net assets worth CN¥1.17 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.59 Billion) and total liabilities (CN¥420.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.17 Billion |
| % of Total Assets | 73.48% |
| Annual Growth Rate | 28.14% |
| 5-Year Change | 32.24% |
| 10-Year Change | N/A |
| Growth Volatility | 46.03 |
Shanghai General Healthy Information and Technology Co. Ltd. - Net Assets Trend (2016–2024)
This chart illustrates how Shanghai General Healthy Information and Technology Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai General Healthy Information and Technology Co. Ltd. (2016–2024)
The table below shows the annual net assets of Shanghai General Healthy Information and Technology Co. Ltd. from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.16 Billion | +2.01% |
| 2023-12-31 | CN¥1.14 Billion | +5.03% |
| 2022-12-31 | CN¥1.08 Billion | +11.04% |
| 2021-12-31 | CN¥975.54 Million | +11.16% |
| 2020-12-31 | CN¥877.62 Million | +149.95% |
| 2019-12-31 | CN¥351.11 Million | +37.39% |
| 2018-12-31 | CN¥255.56 Million | +43.22% |
| 2017-12-31 | CN¥178.44 Million | +11.75% |
| 2016-12-31 | CN¥159.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai General Healthy Information and Technology Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1370.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥541.47 Million | 50.53% |
| Common Stock | CN¥136.00 Million | 12.69% |
| Other Comprehensive Income | CN¥-16.53 Million | -1.54% |
| Other Components | CN¥410.71 Million | 38.33% |
| Total Equity | CN¥1.07 Billion | 100.00% |
Shanghai General Healthy Information and Technology Co. Ltd. Competitors by Market Cap
The table below lists competitors of Shanghai General Healthy Information and Technology Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Karnell
ST:KARNEL-B
|
$195.82 Million |
|
Provident Bancorp Inc
NASDAQ:PVBC
|
$195.90 Million |
|
Jiujiang Shanshui Technology Co.Ltd
SHE:301190
|
$195.92 Million |
|
VTEX
NYSE:VTEX
|
$195.95 Million |
|
Hunan Xiangjia Animal Husbandry Co
SHE:002982
|
$195.67 Million |
|
Eveready Industries India Limited
NSE:EVEREADY
|
$195.62 Million |
|
STROEER (UNSP.ARD)/4/1
F:SAXB
|
$195.59 Million |
|
DAIKI ALUM. IND.
F:7YB
|
$195.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai General Healthy Information and Technology Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,052,726,420 to 1,071,647,096, a change of 18,920,676 (1.8%).
- Net income of 32,520,676 contributed positively to equity growth.
- Dividend payments of 16,413,952 reduced retained earnings.
- Other comprehensive income decreased equity by 16,532,307.
- Other factors increased equity by 19,346,259.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥32.52 Million | +3.03% |
| Dividends Paid | CN¥16.41 Million | -1.53% |
| Other Comprehensive Income | CN¥-16.53 Million | -1.54% |
| Other Changes | CN¥19.35 Million | +1.81% |
| Total Change | CN¥- | 1.80% |
Book Value vs Market Value Analysis
This analysis compares Shanghai General Healthy Information and Technology Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 24.61x to 2.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.86 | CN¥21.23 | x |
| 2017-12-31 | CN¥1.18 | CN¥21.23 | x |
| 2018-12-31 | CN¥1.91 | CN¥21.23 | x |
| 2019-12-31 | CN¥2.11 | CN¥21.23 | x |
| 2020-12-31 | CN¥5.98 | CN¥21.23 | x |
| 2021-12-31 | CN¥6.63 | CN¥21.23 | x |
| 2022-12-31 | CN¥7.39 | CN¥21.23 | x |
| 2023-12-31 | CN¥7.72 | CN¥21.23 | x |
| 2024-12-31 | CN¥7.91 | CN¥21.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai General Healthy Information and Technology Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.22%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.37x
- Recent ROE (3.03%) is below the historical average (19.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.99% | 8.58% | 0.80x | 2.19x | CN¥5.86 Million |
| 2017 | 45.75% | 23.77% | 0.88x | 2.18x | CN¥43.29 Million |
| 2018 | 38.13% | 29.10% | 0.72x | 1.82x | CN¥55.06 Million |
| 2019 | 31.95% | 30.61% | 0.62x | 1.68x | CN¥63.14 Million |
| 2020 | 11.77% | 33.38% | 0.29x | 1.23x | CN¥14.42 Million |
| 2021 | 13.05% | 24.02% | 0.43x | 1.25x | CN¥27.47 Million |
| 2022 | 11.51% | 35.89% | 0.27x | 1.19x | CN¥15.18 Million |
| 2023 | 5.70% | 19.51% | 0.23x | 1.25x | CN¥-45.27 Million |
| 2024 | 3.03% | 10.22% | 0.22x | 1.37x | CN¥-74.64 Million |
Industry Comparison
This section compares Shanghai General Healthy Information and Technology Co. Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,121,810,098
- Average return on equity (ROE) among peers: 128.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai General Healthy Information and Technology Co. Ltd. (605186) | CN¥1.17 Billion | 14.99% | 0.36x | $195.75 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $1.03 Billion | 22.10% | 0.17x | $320.58 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $6.16 Billion | 12.22% | 0.29x | $2.80 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $405.66 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $21.45K | 1180.66% | 90.26x | $283.55 Million |
| Lepu Medical Tech Beijing (300003) | $7.03 Billion | 12.79% | 0.82x | $2.80 Billion |
| INKON Life Technology Co Ltd (300143) | $74.89 Million | 13.27% | 0.87x | $630.90 Million |
| Edan Instruments Inc (300206) | $152.19 Million | 30.16% | 0.31x | $509.86 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.29 Billion | -5.53% | 0.94x | $378.42 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $269.46 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $952.60 Million |